

- chest, 1443
 extremities, 1443
 head and neck, 1443
 heart inspection and palpation, 1446–1447
 jugular venous pressure and waveform, 1443–1444, 1444f
 skin, 1442–1443
 in sleep, 187
- Cardioversion
 anticoagulation before, 1485, 1485t, 1487
 for atrial fibrillation, 1487
 for atrial flutter, 1485
 for cardiac arrest, 1769
 for preexcited tachycardias, 1482
- Care coordination, for elderly, 83–84, 83t
- Caregiver(s), 65–66, 93e–4–5
- Caregiving ratios, 93e–4–5
- Caretaker genes, 101e–2, 101e–5
- Carey–Coombs murmur, 51e–6
- Carfilzomib, 102e–5t, 103e–18t, 103e–19, 717
- Caries, dental, 46e–4f, 236, 1097
- Carisoprodol, 473e–10t
- Carmustine (BCNU)
 adverse effects of, 103e–9t, 607t, 1714
 drug interactions of, 103e–10t
 for melanoma, 499
- Carney's syndrome/complex (LAMB/NAME syndrome)
 adrenal nodules in, 2314, 2321, 2343
 clinical features of, 2265t, 2266, 2343
 genetic considerations in, 2266, 2337t, 2344
 myxoma in, 289e–1
 skin manifestations of, 359, 360t, 1443
- Carnitine deficiency, 435e–1t
- Carnitine metabolism disorders, 1563, 1565
- Carnitine palmitoyltransferase (CPT), 462e–15
- L-Carnitine therapy, 63
- Caroli's disease/syndrome, 552, 1853, 2068
- Carotenemia, 96e–7
- Carotenoderma, 279
- Carotenoids, 96e–6, 96e–7
- Carotid artery
 embryonic development of, 265e–11
 intima media thickness, 1241
 occlusion of, 386e–4f, 2574, 2574f, 2575f.
See also Carotid stenosis
- Carotid artery pulse, 1445, 1445f
- Carotid body, 47e–1
- Carotid cavernous fistula, 207
- Carotid sinus hypersensitivity, 1467t, 1469, 1470, 1471, 1471t
- Carotid sinus massage, 148
- Carotid sinus pressure, PSVT, 1484
- Carotid sinus stimulation, 1625
- Carotid stenosis. *See also* Atherosclerosis
 asymptomatic, surgical treatment of, 2571
 risk factors for, 2569
 stroke due to, 2565, 2567t
 treatment of, 296e–5, 296e–5f, 2571
- Carpal tunnel syndrome
 in acromegaly, 2241
 in amyloidosis, 724
 conditions associated with, 2221
 neck pain in, 122
 in pregnancy, 49
 in systemic sclerosis, 2162
 wrist pain in, 2221
- Carpenter's syndrome, 415e–5t
- Carriers, 332e–6
- Carrión's disease, 1081t, 1083
- cART. *See* Combination antiretroviral therapy (cART)
- Cartilage
 engineered tissue for replacement of, 92e–3t
 joint failure related to, 2227, 2227f
 regeneration of, for osteoarthritis, 2233
- Cartilage hair hypoplasia, 375e–2, 418, 2109
- Carvajal syndrome, 1555t
- Carvalho's sign, 51e–3, 51e–4, 1506, 1540
- Carvedilol
 genetic variations in response to, 39t, 40
 for heart failure, 1512t
 for hypertension, 1624, 1624t
 metabolism of, 34t
 overdose/poisoning with, 473e–9t
- Casal's necklace, 96e–4
- Cascara, 273
- Case-control study, 442t
- Caseous necrosis, 1107
- Case reports, 25
- CASPAR (Classification Criteria for Psoriatic Arthritis), 2177, 2177t
- Caspase, 102e–8, 102e–9f, 372e–23, 444e–9
- Caspase-8, 102e–8, 102e–10
- Caspofungin
 for *Candida* infections, 233, 1344t, 1345, 1910
 for febrile neutropenia, 491
 indications for, 1331
 for infections in cancer patient, 686
 for mucormycosis, 1352t
 for sepsis/septic shock, 1757t
- CaSR gene mutations, 2092, 2340, 2475
- Cast(s), urinary, 62e–11–12f, 294
- Castell's method, splenic percussion, 411
- Castelo dos Sonhos virus, 1307t
- Castleman's disease
 vs. AA amyloidosis, 723
 HHV-8 and, 214e–7, 697, 924, 1194
 vs. lymphoma, 710
 multicentric, in HIV infection, 1271
 paraneoplastic pemphigus and, 372
 treatment of, 710
 vs. tuberculosis, 1109
- Cat(s)
 bite-wounds, 167e–1
 approach to the patient, 167e–2
 cellulitis in, 830
 infections from, 167e–1, 183e–3
 microbiology of, 167e–1
 prophylactic therapy, 167e–3
 treatment of, 167e–2–3, 167e–3t, 832t
- cat-scratch disease. *See* Cat-scratch disease
- fleas, 1078, 2750
 in *T. gondii* life cycle, 1399, 1399f
 tapeworms, 1435
- Catagen, 331
- Catalepsy, 1771
- Catalogue of Somatic Mutations in Cancer (COSMIC), 101e–8
- Catamenial epilepsy, 2559
- Cataplexy, 147, 190, 194v
- Cataract
 etiology of, 204
 in HSCT recipient, 139e–3
 radiation-induced, 103e–4, 623
 sunflower, 2519
 surgical treatment of, 204
 tamoxifen use and, 531
 visual loss in, 204
- Catatonia, 1771
- Catecholamine(s)
 in cardiovascular regulation, 1613
 in pheochromocytoma, 2329, 2330t
 as tumor marker, 473t
- Catecholaminergic polymorphic ventricular tachycardia, 147, 1498
- Catechol-O-methyltransferase (COMT)
 inhibitors, 2615, 2616t
- Caterpillar stings/dermatitis, 2750
- Cat eye syndrome, 83e–6
- Catfish sting, 2740
- Cathartics, 473e–6
- Catheter ablation
 for accessory pathway, 1483
 for atrial fibrillation, 1489
 for atrial flutter, 1485
 for AV nodal reentrant tachycardia, 1480
 for cardiac arrhythmias, 273e–5–7, 273e–6f
 for focal atrial tachycardia, 1475
 for ventricular arrhythmias, 1477, 1499–1500
- Catheter-related bloodstream infections
 in cancer patient, 487, 487t, 489
Candida, 98e–7, 915
 diagnosis of, 916
 enterococcal, 973
 exit-site, 487, 487t
 gram-negative bacteria in, 183e–3
 with parenteral nutrition, 98e–7–8
 pathophysiology of, 915
 prevention of, 12e–2, 914t, 916
 in transplant recipient, 919, 928
 treatment of, 916
 tunnel-site, 487, 487t
- Catheter-related urinary tract infections, 868, 913–914, 914t
- Cathinones, synthetic (bath salts), 469e–3–4
- Cation-exchange resin, for hyperkalemia, 312
- Cation transport disorders, 653
- Cat-scratch disease
 approach to the patient, 1079–1080
 clinical features of, 1079, 1080–1081f
 diagnosis of, 1079
 epidemiology of, 1078
 etiology of, 1078
 in HIV infection, 1268
 lymphadenopathy in, 408
 ocular involvement in, 1081f
 pathogenesis of, 1079
 prevention of, 1080
 skin manifestations of, 829, 1080f
 treatment of, 1080, 1081t
- Catu virus, 1309t
- Cauda equina syndrome
 clinical features of, 115, 1791
 diagnosis of, 115
 treatment of, 115
 weakness in, 156, 157
- Caudal dysplasia, 48
- Causalgia, 90, 105
- Cautious gait, 163
- Cavernomas, 441e–38f
- Cavernous angiomas, 2586
- Cavernous malformations, 440e–7f
- Cavernous sinus syndrome, 2650, 2650f
- Cavernous sinus thrombosis, septic, 783, 906
- CBC (complete blood count), 393, 394t
- CBFA2 gene mutations, 431t
- CBG (corticosteroid-binding globulin), 2378
- CBG (cortisol-binding globulin), 2312
- CBL gene mutations, 135e–6
- CBT. *See* Cognitive behavioral therapy (CBT)
- CBX2 gene mutations, 2354t
- CCBs. *See* Calcium channel blockers (CCBs)
- C-C chemokine family, 372e–14, 372e–14t
- CCI (corrected count increment), 138e–3
- CCK (cholecystokinin), 415e–2, 2090
- CCK (cholecystokinin)-releasing factor, 2091
- CCL2 gene, 1240t, 1241
- CCL3 gene, 1240t, 1241
- CCL4L gene, 1240t
- CCL5 gene, 1240t
- CCL11. *See* Eotaxin (CCL11)
- CCL17 (TARC), 372e–12t, 1674, 1674f
- CCL22 (MDC), 372e–12t, 1674, 1674f
- CCNU (lomustine), 103e–9t, 601
- CCR1, 372e–13t
- CCR2, 372e–13t
- CCR2 receptor, 1240t
- CCR3, 372e–13t, 1674
- CCR4, 372e–13t
- CCR5 receptor
 assays of, 1248–1249
 in HIV infection
 pathogenesis, 145e–1, 145e–2t, 145e–4, 372e–31, 1235–1236, 1236f, 1238
 susceptibility and response, 1239, 1240t, 1241t
 viral replication cycle, 1216, 1218f
 ligands, cell types, and disease connection, 372e–13t
 maraviroc response and, 39t, 1239, 1280f
- CCR6, 372e–13t
- CCR7, 372e–13t
- CCR8, 372e–13t
- CCR9, 372e–13t
- CCR10, 372e–13t
- CD1a (T6, HTA-1), 372e–3t
- CD1b, 372e–3t
- CD1c, 372e–3t
- CD1d, 372e–3t
- CD2 (T12, LFA-2), 372e–3t